Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFßR1 Inhibitor as an Immuno-oncology Agent.
ACS Med Chem Lett
; 11(2): 172-178, 2020 Feb 13.
Article
in En
| MEDLINE
| ID: mdl-32071685
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
ACS Med Chem Lett
Year:
2020
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Estados Unidos